Floatz logo

Everolimus

Recurrent Hepatitis C

Novartis PharmaceuticalsSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Recurrent Hepatitis C cohort.

Asset / SponsorPhaseRating
PARITAPREVIR
AbbVie
Phase 4A
Daclatasvir
MTI University
Phase 4A
Velpatasvir
Peking University People's Hospital
Phase 4A
GLECAPREVIR
AbbVie
Phase 3A
Abt-530
AbbVie
Phase 3A

View all 50 →

Same molecule, other indications

Everolimus is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →